Dive Brief: The Food and Drug Administration approved the antibody treatment Enhertu for earlier use in breast cancer patients, the latest milestone for a drug …
Dive Brief: AstraZeneca and Daiichi Sankyo’s antibody drug Enhertu could become standard treatment for a large group of breast cancer patients following Phase 3 study …
Dive Brief: Amgen will team with Arrakis Therapeutics to develop oral drugs that target and destroy RNA, announcing a deal Tuesday that will pay the Waltham, …
AstraZeneca is betting that Ionis’ second drug for transthyretin amyloidosis, or ATTR, will stand out where its first one couldn’t. Ionis developed Tegsedi for years …
AstraZeneca’s drug, called Evusheld, is the fifth COVID-19 antibody treatment authorized by the FDA, and the fourth now available after Lilly pulled one of its …
The upcoming FDA meeting is critical for FibroGen. CEO Enrique Conterno told analysts on a conference call this week that he believes the company has …
In some ways, AstraZeneca’s COVID-19 response has been as good as any in the biopharmaceutical industry. The British drugmaker licensed and developed an effective COVID-19 …
The FDA has been under pressure to review the status of drugs granted accelerated approvals based on early data, as in some cases confirmatory trials …
The success of the mRNA vaccines developed by Moderna and BioNTech has drawn significant attention, and new funding, to the technology that allows drug developers …
Should detailed study results bear out ALXN1480’s benefit and lead to an FDA approval, the experimental drug could become an important new option for people …
Benlysta’s approval was itself a landmark, being the first such drug approved in decades. Its use has grown slowly and steadily over time, falling just …
AstraZeneca on Wednesday revealed new results from a large U.S. trial of its coronavirus vaccine, responding to a rare rebuke from U.S. officials who publicly …
